Article information
La anidulafungina es una nueva equinocandina que actúa inhibiendo la pared celular de los hongos mediante la inhibición de la síntesis de (1,3)-β-D-glucano. Es un lipopéptido semisintético sintetizado a partir de un compuesto obtenido en la fermentación de Aspergillus nidulans. El espectro de actividad de la anidulafungina incluye Candida y Aspergillus, los dos principales agentes etiológicos de la infección fúngica invasora. Asimismo, es activa frente a cepas de estos géneros que presentan resistencia a los azoles o a la anfotericina B. Sin embargo, carecen de actividad contra Cryptococcus spp. y Trichosporon spp., Fusarium spp. y Mucorales. La información disponible de su actividad contra otras especies es limitada y no permite sacar conclusiones o establecer recomendaciones. La resistencia a las equinocandinas es un hecho infrecuente y con poca relevancia clínica.
Palabras clave:
Anidulafungina
Resistencia in vitro
Candida
Aspergillus
Anidulafungin is a new echinocandin that acts by inhibiting (1,3)-β-D-glucan synthesis in the fungal cell wall. This agent is a semisynthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. The spectrum of activity of anidulafungin includes Candida and Aspergillus, the two main etiological agents causing invasive fungal infections. This drug is also active against strains of these genera resistant to azoles or amphotericin B. However, anidulafungin is not active against Cryptococcus spp., Trichosporon spp., Fusarium spp. or Mucorales spp. Data on the activity of this drug against other species are limited and do not allow conclusions to be drawn or recommendations to be made. Echinocandin resistance is uncommon and has little clinical relevance.
Key words:
Anidulafungin
In vitro resistance
Candida
Aspergillus
Full text is only aviable in PDF
Bibliografía
[1.]
P. De la Torre, A.C. Reboli.
Anidulafungin: a new echinocandin for candidal infections.
Expert Rev Anti Infect Ther, 5 (2007), pp. 45-52
[2.]
J. Vazquez, J. Sobel.
Reviews of antiinfective agents: anidulafungin: a novel echinocandin.
Clin Infect Dis, 43 (2006), pp. 215-222
[3.]
M.A. Pfaller, L. Boyken, R.J. Hollis, J. Kroeger, S.A. Messer, S. Tendolkar, et al.
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
J Clin Microbiol, 46 (2008), pp. 150-156
[4.]
M. Cuenca-Estrella, E. Mellado, T.M. Diaz-Guerra, A. Monzon, J.L. Rodriguez-Tudela.
Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
J Antimicrob Chemother, 46 (2000), pp. 475-477
[5.]
National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A-Second edition. 2002. Wayne: National Committee for Clinical Laboratory Standards; 2002.
[6.]
Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398-405.
[7.]
B. Almirante, D. Rodriguez, B.J. Park, M. Cuenca-Estrella, A.M. Planes, M. Almela, et al.
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003.
J Clin Microbiol, 43 (2005), pp. 1829-1835
[8.]
A. Gomez-Lopez, A. Alastruey-Izquierdo, D. Rodriguez, B. Almirante, A. Pahissa, J.L. Rodriguez-Tudela, et al.
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis. results from population-based surveillance of candidemia in Spain.
Antimicrob Agents Chemother, 52 (2008), pp. 1506-1509
[9.]
National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. 2002. Wayne: National Committee for Clinical Laboratory Standards; 2002.
[10.]
J.L. Rodriguez-Tudela, M.C. Arendrup, S. Arikan, F. Barchisei, J. Bille, E. Chryssantou, et al.
Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds.
UCAST, (2008),
[11.]
S. Arikan, M. Lozano-Chiu, V. Paetznick, J.H. Rex.
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.
Antimicrob Agents Chemother, 45 (2001), pp. 327-330
[12.]
A. Espinel-Ingroff, A. Fothergill, M. Ghannoum, E. Manavathu, L. Ostrosky-Zeichner, M.A. Pfaller, et al.
Quality Control and reference guidelines for CLSI broth microdilution method (M38-A Document) for susceptibility testing of anidulafungin against molds.
J Clin Microbiol, 45 (2007), pp. 2180-2182
[14.]
M.D. Serrano, A. Valverde-Conde, M. Chaveza, S. Bernal, R.M. Claro, J. Peman, et al.
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp.
Diagn Microbiol Infect Dis, 45 (2003), pp. 131-135
[15.]
Z. Odabasi, V.L. Paetznick, J.R. Rodriguez, E. Chen, L. Ostrosky-Zeichner.
In vitro activity of anidulafungin against selected clinically important mold isolates.
Antimicrob Agents Chemother, 48 (2004), pp. 1912-1915
[16.]
M.A. Pfaller, F. Marco, S.A. Messer, R.N. Jones.
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.
Diagn Microbiol Infect Dis, 30 (1998), pp. 251-255
[17.]
G.G. Zhanel, J.A. Karlowsky, G.A. Harding, T.V. Balko, S.A. Zelenitsky, M. Friesen, et al.
In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.
Antimicrob Agents Chemother, 41 (1997), pp. 863-865
[18.]
C. Antachopoulos, J. Meletiadis, T. Sein, E. Roilides, T.J. Walsh.
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
Antimicrob Agents Chemother, 52 (2008), pp. 321-328
[19.]
C. Antachopoulos, J. Meletiadis, T. Sein, E. Roilides, T.J. Walsh.
Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.
Antimicrob Agents Chemother, 51 (2007), pp. 881-887
[20.]
J.C. Bowman, G.K. Abruzzo, A.M. Flattery, C.J. Gill, E.J. Hickey, M.J. Hsu, et al.
Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans.
Antimicrob Agents Chemother, 50 (2006), pp. 4202-4205
[21.]
J. Maertens, I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. Petersen, et al.
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Clin Infect Dis, 39 (2004), pp. 1563-1571
[22.]
S. Arikan, V. Paetznick, J.H. Rex.
Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates.
Antimicrob Agents Chemother, 46 (2002), pp. 3084-3087
[23.]
S. Arikan, P. Yurdakul, G. Hascelik.
Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp.
Antimicrob Agents Chemother, 47 (2003), pp. 2640-2643
[24.]
A. Espinel-Ingroff, B. Arthington-Skaggs, N. Iqbal, D. Ellis, M.A. Pfaller, S. Messer, et al.
Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
J Clin Microbiol, 45 (2007), pp. 1811-1820
[25.]
A. Espinel-Ingroff, E. Canton.
Comparison of neo-sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for susceptibility testing of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole and voriconazole.
J Clin Microbiol, (2008),
[26.]
A. Espinel-Ingroff.
Evaluation of broth microdilution testing parameters and agar diffusion etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).
J Clin Microbiol, 41 (2003), pp. 403-409
[27.]
A.S. Ibrahim, T. Gebremariam, Y. Fu, J.E. Edwards Jr., B. Spellberg.
Combination echinocandin-polyene treatment of murine mucormycosis.
Antimicrob Agents Chemother, 52 (2008), pp. 1556-1558
[28.]
A. Philip, Z. Odabasi, J. Rodriguez, V.L. Paetznick, E. Chen, J.H. Rex, et al.
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Antimicrob Agents Chemother, 49 (2005), pp. 3572-3574
[29.]
M. Cuenca-Estrella, A. Alastruey-Izquierdo, L. Alcazar-Fuoli, L. Bernal-Martinez, A. Gomez-Lopez, M.J. Buitrago, et al.
In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans.
Antimicrob Agents Chemother, 52 (2008), pp. 1136-1139
[30.]
M.T. Baixench, N. Aoun, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, S. Ramires, et al.
Acquired resistance to echinocandins in Candida albicans: case report and review.
J Antimicrob Chemother, 59 (2007), pp. 1076-1083
[31.]
S. Hernandez, J.L. Lopez-Ribot, L.K. Najvar, D.I. McCarthy, R. Bocanegra, J.R. Graybill.
Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.
Antimicrob Agents Chemother, 48 (2004), pp. 1382-1383
[32.]
J.N. Kahn, G. Garcia-Effron, M.J. Hsu, S. Park, K.A. Marr, D.S. Perlin.
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.
Antimicrob Agents Chemother, 51 (2007), pp. 1876-1878
[33.]
S. Katiyar, M. Pfaller, T. Edlind.
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.
Antimicrob Agents Chemother, 50 (2006), pp. 2892-2894
[34.]
M. Krogh-Madsen, M. Arendrup, L. Heslet, J. Knudsen.
Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically Ill patient.
Clin Infect Dis, 42 (2006), pp. 938-944
[35.]
M. Laverdiere, R.G. Lalonde, J.G. Baril, D.C. Sheppard, S. Park, D.S. Perlin.
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.
J Antimicrob Chemother, 57 (2006), pp. 705-708
[36.]
V. Moudgal, T. Little, D. Boikov, J.A. Vazquez.
Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.
Antimicrob Agents Chemother, 49 (2005), pp. 767-769
[37.]
S. Park, R. Kelly, J.N. Kahn, J. Robles, M.J. Hsu, E. Register, et al.
Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Antimicrob Agents Chemother, 49 (2005), pp. 3264-3273
[38.]
T. Pasquale, J.R. Tomada, M. Ghannoun, J. Dipersio, H. Bonilla.
Emergence of Candida tropicalis resistant to caspofungin.
J Antimicrob Chemother, 61 (2008), pp. 219
[39.]
D.S. Perlin.
Resistance to echinocandin-class antifungal drugs.
Drug Resistance Updates, 10 (2007), pp. 121-130
[40.]
E.M. Rocha, G. Garcia-Effron, S. Park, D.S. Perlin.
A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus.
Antimicrob Agents Chemother, 51 (2007), pp. 4174-4176
[41.]
G. Chamilos, R.E. Lewis, N. Albert, D.P. Kontoyiannis.
Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandinspecific and Candida species-related differences.
Antimicrob Agents Chemother, 51 (2007), pp. 2257-2259
[42.]
K.V. Clemons, M. Espiritu, R. Parmar, D.A. Stevens.
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.
Antimicrob Agents Chemother, 50 (2006), pp. 1293-1297
[43.]
D.A. Stevens, M. Espiritu, R. Parmar.
Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.
Antimicrob Agents Chemother, 48 (2004), pp. 3407-3411
[44.]
D.A. Stevens, M. Ichinomiya, Y. Koshi, H. Horiuchi.
Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for {beta}-1,6-glucan synthesis inhibition by caspofungin.
Antimicrob Agents Chemother, 50 (2006), pp. 3160-3161
[45.]
N.P. Wiederhold, D.P. Kontoyiannis, R.A. Prince, R.E. Lewis.
Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways.
Antimicrob Agents Chemother, 49 (2005), pp. 5146-5148
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
